The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Authors:
- James R. CerhanJCJames R. Cerhan
- Matthew J. MaurerMMMatthew J. Maurer
- Brian K. LinkBLBrian K. Link
- Andrew L. FeldmanAFAndrew L. Feldman
- Thomas M. HabermannTHThomas M. Habermann
- David L. JayeDJDavid L. Jaye
- W. Richard BurackWBW. Richard Burack
- Francisco VegaFVFrancisco Vega
- Jennifer R. ChapmanJCJennifer R. Chapman
- Sergei SyrbuSSSergei Syrbu
- Kiran R. VijKVKiran R. Vij
- 13 January 2024
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 99 (3) , 408-421
Abstract
To address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.Keywords
Funding Information
- National Cancer Institute (U01 CA195568)
This publication has 40 references indexed in Scilit:
- Racial differences in the presentation and outcomes of diffuse large B‐cell lymphoma in the United StatesCancer, 2010
- The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service researchBritish Journal of Haematology, 2010
- Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global itemsQuality of Life Research, 2009
- Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United StatesLeukemia & Lymphoma, 2008
- Prognostic significance of host immune gene polymorphisms in follicular lymphoma survivalBlood, 2007
- The rationale, design, and implementation of the American Cancer Society's studies of cancer survivorsCancer, 2006
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British ColumbiaJournal of Clinical Oncology, 2005
- The Vulnerable Elders Survey: A Tool for Identifying Vulnerable Older People in the CommunityJournal of the American Geriatrics Society, 2001
- Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD): Study design and methodsAmerican Heart Journal, 2000